Anti-CD20 antibody (rituximab) administration in patients with late-occurring lymphomas after solid organ transplant

G. Dotti, A. Rambaldi, R. Fiocchi, T. Motta, G. Torre, P. Viero, B. Gridelli, T. Barbui

Research output: Contribution to journalArticle

Abstract

Background and Objectives. Aggressive diffuse large cell non-Hodgkin's lymphoma (DLCL) occurring late after a solid organ transplant fails to regress after discontinuation of immunosuppression. Moreover, chemotherapy treatment is associated with a high mortality rate due to severe toxicity. Since the majority of post-transplant lymphoproliferative disorders derive from B-lineage lymphocytes, the administration of anti-B monoclonal antibodies represents a rational therapeutic option. Design and Methods. Five patients who developed CD20-positive DLCL more than two years after heart or liver transplantation were treated with a weekly chemotherapy program (2 patients), radiotherapy (2 patients) and surgery (1 patient) followed by a minimum of 4 intravenous doses of rituximab (375 mg/m2). Results. A favorable clinical outcome was observed in three patients in whom surgery or radiotherapy had produced significant tumor debulking. Only a partial clinical effect was documented in the two patients with advanced clinical stage disease. Interpretation and Conclusions. Rituximab can be safely administered to patients with aggressive CD20-positive DLCL occurring late after a solid organ transplant. However, a positive clinical outcome may be expected only in patients in whom surgery or radiotherapy has achieved significant regression of tumor burden.

Original languageEnglish
Pages (from-to)618-623
Number of pages6
JournalHaematologica
Volume86
Issue number6
Publication statusPublished - 2001

Fingerprint

Anti-Idiotypic Antibodies
Lymphoma
Transplants
Non-Hodgkin's Lymphoma
Radiotherapy
Drug Therapy
Lymphoproliferative Disorders
Rituximab
Heart Transplantation
Tumor Burden
Liver Transplantation
Immunosuppression
Monoclonal Antibodies
Lymphocytes
Mortality
Therapeutics
Neoplasms

Keywords

  • Allogeneic bone marrow transplant
  • Immunosuppression
  • Immunotherapy
  • PTLD
  • Rituximab
  • Solid organ transplant

ASJC Scopus subject areas

  • Hematology

Cite this

Dotti, G., Rambaldi, A., Fiocchi, R., Motta, T., Torre, G., Viero, P., ... Barbui, T. (2001). Anti-CD20 antibody (rituximab) administration in patients with late-occurring lymphomas after solid organ transplant. Haematologica, 86(6), 618-623.

Anti-CD20 antibody (rituximab) administration in patients with late-occurring lymphomas after solid organ transplant. / Dotti, G.; Rambaldi, A.; Fiocchi, R.; Motta, T.; Torre, G.; Viero, P.; Gridelli, B.; Barbui, T.

In: Haematologica, Vol. 86, No. 6, 2001, p. 618-623.

Research output: Contribution to journalArticle

Dotti, G, Rambaldi, A, Fiocchi, R, Motta, T, Torre, G, Viero, P, Gridelli, B & Barbui, T 2001, 'Anti-CD20 antibody (rituximab) administration in patients with late-occurring lymphomas after solid organ transplant', Haematologica, vol. 86, no. 6, pp. 618-623.
Dotti, G. ; Rambaldi, A. ; Fiocchi, R. ; Motta, T. ; Torre, G. ; Viero, P. ; Gridelli, B. ; Barbui, T. / Anti-CD20 antibody (rituximab) administration in patients with late-occurring lymphomas after solid organ transplant. In: Haematologica. 2001 ; Vol. 86, No. 6. pp. 618-623.
@article{bf5a13debe58467cb99e7285d5e88d06,
title = "Anti-CD20 antibody (rituximab) administration in patients with late-occurring lymphomas after solid organ transplant",
abstract = "Background and Objectives. Aggressive diffuse large cell non-Hodgkin's lymphoma (DLCL) occurring late after a solid organ transplant fails to regress after discontinuation of immunosuppression. Moreover, chemotherapy treatment is associated with a high mortality rate due to severe toxicity. Since the majority of post-transplant lymphoproliferative disorders derive from B-lineage lymphocytes, the administration of anti-B monoclonal antibodies represents a rational therapeutic option. Design and Methods. Five patients who developed CD20-positive DLCL more than two years after heart or liver transplantation were treated with a weekly chemotherapy program (2 patients), radiotherapy (2 patients) and surgery (1 patient) followed by a minimum of 4 intravenous doses of rituximab (375 mg/m2). Results. A favorable clinical outcome was observed in three patients in whom surgery or radiotherapy had produced significant tumor debulking. Only a partial clinical effect was documented in the two patients with advanced clinical stage disease. Interpretation and Conclusions. Rituximab can be safely administered to patients with aggressive CD20-positive DLCL occurring late after a solid organ transplant. However, a positive clinical outcome may be expected only in patients in whom surgery or radiotherapy has achieved significant regression of tumor burden.",
keywords = "Allogeneic bone marrow transplant, Immunosuppression, Immunotherapy, PTLD, Rituximab, Solid organ transplant",
author = "G. Dotti and A. Rambaldi and R. Fiocchi and T. Motta and G. Torre and P. Viero and B. Gridelli and T. Barbui",
year = "2001",
language = "English",
volume = "86",
pages = "618--623",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Anti-CD20 antibody (rituximab) administration in patients with late-occurring lymphomas after solid organ transplant

AU - Dotti, G.

AU - Rambaldi, A.

AU - Fiocchi, R.

AU - Motta, T.

AU - Torre, G.

AU - Viero, P.

AU - Gridelli, B.

AU - Barbui, T.

PY - 2001

Y1 - 2001

N2 - Background and Objectives. Aggressive diffuse large cell non-Hodgkin's lymphoma (DLCL) occurring late after a solid organ transplant fails to regress after discontinuation of immunosuppression. Moreover, chemotherapy treatment is associated with a high mortality rate due to severe toxicity. Since the majority of post-transplant lymphoproliferative disorders derive from B-lineage lymphocytes, the administration of anti-B monoclonal antibodies represents a rational therapeutic option. Design and Methods. Five patients who developed CD20-positive DLCL more than two years after heart or liver transplantation were treated with a weekly chemotherapy program (2 patients), radiotherapy (2 patients) and surgery (1 patient) followed by a minimum of 4 intravenous doses of rituximab (375 mg/m2). Results. A favorable clinical outcome was observed in three patients in whom surgery or radiotherapy had produced significant tumor debulking. Only a partial clinical effect was documented in the two patients with advanced clinical stage disease. Interpretation and Conclusions. Rituximab can be safely administered to patients with aggressive CD20-positive DLCL occurring late after a solid organ transplant. However, a positive clinical outcome may be expected only in patients in whom surgery or radiotherapy has achieved significant regression of tumor burden.

AB - Background and Objectives. Aggressive diffuse large cell non-Hodgkin's lymphoma (DLCL) occurring late after a solid organ transplant fails to regress after discontinuation of immunosuppression. Moreover, chemotherapy treatment is associated with a high mortality rate due to severe toxicity. Since the majority of post-transplant lymphoproliferative disorders derive from B-lineage lymphocytes, the administration of anti-B monoclonal antibodies represents a rational therapeutic option. Design and Methods. Five patients who developed CD20-positive DLCL more than two years after heart or liver transplantation were treated with a weekly chemotherapy program (2 patients), radiotherapy (2 patients) and surgery (1 patient) followed by a minimum of 4 intravenous doses of rituximab (375 mg/m2). Results. A favorable clinical outcome was observed in three patients in whom surgery or radiotherapy had produced significant tumor debulking. Only a partial clinical effect was documented in the two patients with advanced clinical stage disease. Interpretation and Conclusions. Rituximab can be safely administered to patients with aggressive CD20-positive DLCL occurring late after a solid organ transplant. However, a positive clinical outcome may be expected only in patients in whom surgery or radiotherapy has achieved significant regression of tumor burden.

KW - Allogeneic bone marrow transplant

KW - Immunosuppression

KW - Immunotherapy

KW - PTLD

KW - Rituximab

KW - Solid organ transplant

UR - http://www.scopus.com/inward/record.url?scp=0034961829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034961829&partnerID=8YFLogxK

M3 - Article

C2 - 11418370

AN - SCOPUS:0034961829

VL - 86

SP - 618

EP - 623

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -